Drug Profile
Izokibep - Affibody
Alternative Names: ABY 035; ABY-035/AFO2; AFB-035; IMG-020; IMG-20Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Affibody
- Developer ACELYRIN; Affibody; Inmagene
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Recombinant fusion proteins
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hidradenitis suppurativa
- Phase II/III Psoriatic arthritis; Uveitis
- Phase II Ankylosing spondylitis; Axial spondyloarthritis; Plaque psoriasis
- Phase I/II Psoriasis
- Phase I Unspecified
Most Recent Events
- 11 Mar 2024 Efficacy and adverse events data from a phase-IIb/III trial in Psoriatic arthritis released by ACELYRIN
- 21 Feb 2024 ACELYRIN completed a phase II/III trial in Hidradenitis suppurativa in USA, Spain, Poland, Hungary, Germany, Canada (SC) (NCT05355805)
- 10 Nov 2023 Updated efficacy and adverse event data from a phase II trial in Psoriatic arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)